Viewing Study NCT05002569


Ignite Creation Date: 2025-12-24 @ 10:46 PM
Ignite Modification Date: 2026-01-01 @ 12:54 PM
Study NCT ID: NCT05002569
Status: TERMINATED
Last Update Posted: 2025-05-18
First Post: 2021-08-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
Sponsor: Bristol-Myers Squibb
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module